Top HER2-positive breast cancer news from SABCS
San Antonio Breast Cancer Symposium 2024 provided multiple updates in the field of HER2-positive breast cancer, including novel treatments, new treatment regimens and more.
See Healio’s highlights in HER2-positive breast cancer coverage below:
1. The novel antibody-drug conjugate SHR-A1811 (Jiangsu Hengrui Therapeutics) exhibited promising antitumor activity as neoadjuvant treatment for patients with HER2-positive breast cancer. Read more.
2. The addition of pyrotinib (Jiangsu Hengrui Therapeutics) to first-line trastuzumab (Herceptin, Genentech) and docetaxel improved PFS among patients with HER2-positive metastatic breast cancer. Read more.
3. The addition of palbociclib (Ibrance, Pfizer) to standard care extended median PFS for patients with hormone receptor-positive, HER2-positive metastatic breast cancer. Read more.
4. Patrick McIntire, MD, discusses findings from the DESTINY-Breast04 and DESTINY-Breast06 trials. Read more.
5. Shimoli Barot, MD, discusses the results of a study observing exceptional treatment response in patients with metastatic breast cancer. Read more.